Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs

Table 1 Influence of factor X concentration on clotting test results

	Undiluted	Dilution	Dilution	Dilution	Dilution	Dilution	Dilution	p
Test	100%	50%	25%	12.50%	6.25%	3.13%	1.56%
R-PT	1	1.18 ± 0.07	1.42 ± 0.04	1.84 ± 0.14	2.09 ± 0.2	2.71 ± 0.08	3.44 ± 0.25	<0.001
R-aPTT	1	0.99 ± 0.14	1.08 ± 0.11	1.22 ± 0.08	1.3 ± 0.1	1.55 ± 0.26	1.8 ± 0.30	<0.001
R-VV	1	1.13 ± 0.07	1.36 ± 0.07	1.55 ± 0.08	1.85 ± 0.11	2.19 ± 0.24	2.73 ± 0.28	<0.001
R-C	1	1.17 ± 0.11	1.46 ± 0.14	1.79 ± 0.12	2.35 ± 0.16	3.11 ± 0.16	4.52 ± 0.33	<0.001
P		0.034	<0.001	<0.001	<0.001	<0.001	<0.001

Dilution 50%: p < 0.05 for R-aPTT vs. R-PT, R-VV and R-C; Dilution 25%: p < 0.01 for R-aPTT vs. R-PT, R-VV, and R-C; Dilution 12,5%: p < 0.01 for R-aPTT vs. R-PT and R-C; p < 0.05 for R-aPTT vs. R-VV; p < 0.05 for R-VV vs. R-C and R-PT; Dilution 6.25%: p < 0.01 for R-C vs. R-aPTT; p < 0.05 for R-C vs. R-VV and R-PT; p < 0.01 for R-PT vs. R-aPTT; p < 0.05 for R-PT vs. R-VV; Dilution 3.13%: p < 0.01 for R-C vs. R-aPTT and R-VV; p < 0.05 for R-C vs. R-PT; p < 0.05 for RaPTT vs. R-VV and R-PT; Dilution 1.56%: p < 0.01 for R-C vs. R-aPTT, R-VV, and R-PT; p < 0.01 for R-aPTT vs. R-VV and R-PT.

ISSN: 1477-9560